Search Result

Results for "

atpase+inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (4) Apoptosis (26) Atg8/LC3 (11) ATP Synthase (7) Autophagy (22) Bacterial (23) Calcium Channel (2) Cytochrome P450 (11) DNA/RNA Synthesis (2) Drug Metabolite (3) EAAT (1) Epigenetic Reader Domain (2) Exosomes (2) Fluorescent Dye (2) Fungal (2) HIV (2) IKK (1) Influenza Virus (1) Interleukin Related (11) Isotope-Labeled Compounds (13) LXR (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Myosin (2) Na+/K+ ATPase (31) p97 (2) PD-1/PD-L1 (1) Proton Pump (42) Ras (1) Reference Standards (12) SARS-CoV (1) STAT (1) STING (1) SWI/SNF Complex (1) TNF Receptor (11) VSV (1)
By Research Areas:	Cancer (45) Cardiovascular Disease (8) Endocrinology (2) Infection (19) Inflammation/Immunology (25) Metabolic Disease (13) Neurological Disease (11)

By Targets:

Antibiotic (4)

Apoptosis (26)

Atg8/LC3 (11)

ATP Synthase (7)

Autophagy (22)

Bacterial (23)

Calcium Channel (2)

Cytochrome P450 (11)

DNA/RNA Synthesis (2)

Drug Metabolite (3)

EAAT (1)

Epigenetic Reader Domain (2)

Exosomes (2)

Fluorescent Dye (2)

Fungal (2)

HIV (2)

IKK (1)

Influenza Virus (1)

Interleukin Related (11)

Isotope-Labeled Compounds (13)

LXR (1)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Myosin (2)

Na+/K+ ATPase (31)

p97 (2)

PD-1/PD-L1 (1)

Proton Pump (42)

Ras (1)

Reference Standards (12)

SARS-CoV (1)

STAT (1)

STING (1)

SWI/SNF Complex (1)

TNF Receptor (11)

VSV (1)

By Research Areas:

Cancer (45)

Cardiovascular Disease (8)

Endocrinology (2)

Infection (19)

Inflammation/Immunology (25)

Metabolic Disease (13)

Neurological Disease (11)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16589

Oligomycin A Maximum Cited Publications 51 Publications Verification MCH 32	ATP Synthase Fungal Antibiotic	Infection Cancer
Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial *F₀F₁-ATPase* inhibitor, with a K_i of 1 μM; Oligomycin A shows anti-fungal activity.

HY-N1724

Concanamycin A 25+ Cited Publications Antibiotic X 4357B; Folimycin; X 4357B	Proton Pump Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research ^- .

HY-B0113

Omeprazole 5+ Cited Publications H 16868	Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related	Infection Neurological Disease Inflammation/Immunology Cancer
Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-N0877

Bufalin 5+ Cited Publications	Na+/K+ ATPase	Cancer
Bufalin is an active component isolated from Chan Su, acts as a potent Na ⁺/K ⁺-ATPase inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-D0085

DiSC3(5) 10+ Cited Publications	Fluorescent Dye	Cancer
DiSC3(5) is a fluorescent probe commonly used as a tracer dye to evaluate mitochondrial membrane potential. The excitation/emission wavelength of DiSC3(5) is up to 622/670 nm. DiSC3(5) can inhibit the respiratory system associated with mitochondrial NAD, and the IC₅₀ value is 8 μM. DiSC3(5) in the presence of Na ⁺/K ⁺-ATPase inhibitor ouabain 2 can induce membrane hyperpolarization of Ehrlich ascites tumor cells .

HY-17022

Esomeprazole magnesium trihydrate 1 Publications Verification (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-17507

Pantoprazole 4 Publications Verification BY1023; SKF96022	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0113A

Omeprazole sodium 5+ Cited Publications H 16868 sodium	Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Inflammation/Immunology
Omeprazole (H 16868) sodium is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-Y0413

Biacetyl monoxime Diacetyl monoxime; DAM	Na+/K+ ATPase Myosin	Cardiovascular Disease Metabolic Disease
Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca ²⁺ release .

HY-B1446

Esomeprazole magnesium 2 Publications Verification (S)-Omeprazole magnesium; (-)-Omeprazole magnesium	Exosomes Proton Pump	Endocrinology Cancer
Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H ⁺, K ⁺-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H ⁺-ATPases .

HY-N2532

Diphyllin 3 Publications Verification	VSV HIV Proton Pump Influenza Virus	Infection Inflammation/Immunology Cancer
Diphyllin is an orally active *V-ATPase* inhibitor (IC₅₀=17 nM) and HIV-1 inhibitor (IC₅₀=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC₅₀=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .

HY-15877

BTB06584 2 Publications Verification	ATP Synthase	Cancer
BTB06584 is a selective and IF1-dependent mitochondrial F₁F_o-ATPase inhibitor without compromising ATP synthesis. BTB06584 can delays ischaemic cell death .

HY-126679

Apoptolidin	ATP Synthase Apoptosis	Cancer
Apoptolidin is a polyketide isolated from Nocardiopsis bacteria . Apoptolidin is a selective mitochondrial F₁F_O ATPase inhibitor. Apoptolidin is an apoptosis inducer and induces apoptotic cell death in cells transformed with the adenovirus type 12 oncogenes including ElA (IC₅₀=10-17 ng/ml) but not in normal cells .

HY-17507A

Pantoprazole sodium 4 Publications Verification BY1023 sodium; SKF96022 sodium	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507B

Pantoprazole sodium hydrate 4 Publications Verification BY1023 sodium hydrate; SKF96022 sodium hydrate	Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0137

Prilocaine 1 Publications Verification	Na+/K+ ATPase	Neurological Disease
Prilocaine, an amino amide, is a *Na/K-ATPase* inhibitor. Prilocaine has neurotoxic effects .

HY-15718A

Istaroxime hydrochloride 5+ Cited Publications PST2744 hydrochloride	Na+/K+ ATPase Calcium Channel	Cardiovascular Disease
Istaroxime hydrochloride is a Na ⁺/K ⁺-ATPase inhibitor (IC₅₀=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA 2) activator.

HY-17623C

(R)-Tegoprazan (R)-CJ-12420; (R)-RQ-00000004	Proton Pump	Metabolic Disease
(R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 98 nM of canine kidney Na ⁺/K ⁺-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research .

HY-136933

Gitoxin	Na+/K+ ATPase	Cardiovascular Disease
Gitoxin is a degradation metabolite of Digitoxin (HY-B1357) and a non-competitive Na ⁺/K ⁺-ATPase inhibitor, with an IC₅₀ of 1.18e-6 M against the porcine high-affinity subtype and an IC₅₀ of 2.85e-5 M against the porcine low-affinity subtype. Gitoxin regulates atrial contractility and rhythmicity. Gitoxin is applicable to research related to congestive heart failure .

HY-176954

RSC-1255	Proton Pump Ras Autophagy Apoptosis	Cancer
RSC-1255 is a potent and selective Vacuolar H⁺-ATPase (V-ATPase) inhibitor that directly binds the mammalian V-ATPase complex with a K_d = 23 nM. RSC-1255 exhibits preferential cytotoxicity toward KRAS-mutant cancer cells, especially KRAS ^G13D and KRAS ^G12V cells. RSC-1255 induces apoptosis and blocks lysosomal acidification, autophagy, and macropinocytosis in cancer cells. RSC-1255 can be used for the study of KRAS-driven lung and colon cancers .

HY-145946

*BRM/BRG1 ATP Inhibitor-2*	Epigenetic Reader Domain	Cancer
BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor for the research of BAF-related disorders.

HY-W754708

Ouabagenin	LXR Na+/K+ ATPase	Cardiovascular Disease
Ouabagenin is a naturally occurring LXR ligand with LXR selective agonist activity. Ouabagenin acts as an EC 3.6.3.9 (Na(+)/K(+)- transport ATPase) inhibitor .

HY-149458

FHT-2344	Epigenetic Reader Domain	Cancer
FHT-2344, a chemical probe, is a SMARCA4/SMARCA2 ATPase inhibitor with IC₅₀ values of 0.026 μM and 0.013 μM, respectively. FHT-2344 has anticancer activity .

HY-DY1021

DiSC3(5) (solution)	Fluorescent Dye	Others
DiSC3 (5) (solution) is a fluorescent probe commonly used as a tracer dye to evaluate mitochondrial membrane potential. The excitation/emission wavelength of DiSC3 (5) is up to 622/670 nm. DiSC3 (5) can inhibit the respiratory system associated with mitochondrial NAD, and the IC₅₀ value is 8 μM. DiSC3 (5) in the presence of Na ⁺/K ⁺-ATPase inhibitor ouabain 2 can induce membrane hyperpolarization of Ehrlich ascites tumor cells . Solvent and concentration: DMSO: 1 mM The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

HY-B0113R

Omeprazole (Standard) H 16868 (Standard)	Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Metabolic Disease Cancer
Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S

Omeprazole-d3 1 Publications Verification H 16868-d₃	Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Metabolic Disease Cancer
Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-19797

ML241	p97	Cancer
ML241 is a potent, selective and competitive p97 ATPase inhibitor with an IC₅₀ of 0.11 μM. ML241 can be used for the research of cancer .

HY-148041

ATPase-IN-2	ATP Synthase	Others
ATPase-IN-2 is an *ATPase* inhibitor with an IC₅₀ value of 0.9 μM. ATPase-IN-2 inhibits C. difficile toxin B (TcdB) glycohydrolase activity with an AC₅₀ value of 30.91 μM. ATPase-IN-2 can be used for the research of ATP-related .

HY-W317853

Protonstatin-1	Proton Pump	Others
Protonstatin-1 is a selective plasma membrane (PM) H ⁺-ATPase inhibitor (IC₅₀ of 3.9 μM) that inhibits auxin transport. Protonstatin-1 interacts with the PM H ⁺-ATPase central loop and may thus impede the functions of the N- and/or P-domain to inhibit the pump activity .

HY-P10655

Caloxin 1C2	Proton Pump Calcium Channel	Cardiovascular Disease
Caloxin 1C2 is a specific PMCA (plasma-membrane Ca ²⁺-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The K_i values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca ²⁺ transfer. Caloxin 1C2 affects coronary contractility .

HY-109546

Omeprazole magnesium	Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Metabolic Disease Cancer
Omeprazole (H 16868) magnesium is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects .

HY-B0113S3

Omeprazole-13C,d3 H 16868-¹³C,d₃	Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3	Infection Metabolic Disease Cancer
Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-123370

FR-167356	Proton Pump	Metabolic Disease Cancer
FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC₅₀ values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .

HY-162935

*V-ATPase-IN-1*	Proton Pump	Others
V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H ⁺-ATPases (V-ATPase) inhibitor (IC₅₀ = 194.80 μM) that can effectively target the *V-ATPase* subunit A (K_d = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC₅₀ = 2.64 mM) and contributes to research in the development of chemical insecticides .

HY-17507AR

Pantoprazole sodium (Standard) BY1023 sodium (Standard); SKF96022 sodium (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-103702

TIP48/49-IN-1	Proton Pump DNA/RNA Synthesis Apoptosis	Inflammation/Immunology Cancer
TIP48/49-IN-1 is an orally active, specific RUVBL1/2 (TIP48/49) ATPase inhibitor with an IC₅₀ of 59 nM against purified RUVBL1/2. TIP48/49-IN-1 inhibits the DNA replication process, leading to S-phase arrest. TIP48/49-IN-1 induces apoptosis. TIP48/49-IN-1 can be used for the research of non-small cell lung cancer (NSCLC) cells .

HY-B0137A

Prilocaine hydrochloride 1 Publications Verification	Na+/K+ ATPase	Neurological Disease
Prilocaine hydrochloride, an amino amide, is a *Na/K-ATPase* inhibitor. Prilocaine has neurotoxic effects .

HY-101646

Saviprazole HOE-731	Proton Pump	Inflammation/Immunology
Saviprazole (HOE-731) is a H ⁺,K ⁺-ATPase inhibitor. Saviprazole inhibits gastric acid secretion. Saviprazole inhibits histamine- and dbcAMP-stimulated [ ¹⁴C]aminopyrine uptake, dbcAMP-induced oxygen consumption. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .

HY-U00222

S3337	Proton Pump	Inflammation/Immunology
S3337 is an H ⁺, K ⁺-ATPase inhibitor.

HY-176850

Myosin-IN-2	Myosin	Cardiovascular Disease
Myosin-IN-2 (Example 16) is a Myosin ATPase inhibitor with a IC₅₀ of 1.06  μM. Myosin-IN-2 can be used for heart diseases like hypertrophic cardiomyopathy (HCM) research .

HY-125714

Isoapoptolidin	Mitochondrial Metabolism ATP Synthase	Neurological Disease Cancer
Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (K_i>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration) .

HY-16589R

Oligomycin A (Standard) MCH 32 (Standard)	Reference Standards ATP Synthase Fungal Antibiotic	Infection Cancer
Oligomycin A (Standard) is the analytical standard of Oligomycin A. This product is intended for research and analytical applications. Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATPase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.

HY-W008614S

Lansoprazole sulfone-d4 AG-1813-d₄	Isotope-Labeled Compounds Proton Pump Drug Metabolite	Inflammation/Immunology
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-124742

AR-HO47108	Na+/K+ ATPase	Others
AR-HO47108 is an orally active reversible Na+/K+ ATPase inhibitor. AR-HO47108 reversibly blocks the final step of gastric acid secretion by competitively binding to the potassium ion binding site of the Na+/K+ ATPase in the gastric wall cells. AR-HO47108 can be used for research on diseases related to excessive gastric acid secretion, such as peptic ulcers .

HY-17507S

Pantoprazole-d6 BY1023-d₆; SKF96022-d₆	Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis	Inflammation/Immunology Cancer
Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507R

Pantoprazole (Standard) BY1023 (Standard); SKF96022 (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507BR

Pantoprazole sodium hydrate (Standard) BY1023 sodium hydrate (Standard); SKF96022 sodium hydrate (Standard)	Reference Standards Proton Pump Autophagy Apoptosis Bacterial	Inflammation/Immunology Cancer
Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0137B

Prilocaine acetate	Na+/K+ ATPase	Neurological Disease
Prilocaine acetate, an amino amide, is a *Na/K-ATPase* inhibitor. Prilocaine acetate has neurotoxic effects .

HY-N9456

14-Anhydrodigitoxigenin	Na+/K+ ATPase	Others
14-Anhydrodigitoxigenin is a cardenolides that can be isolated from the leaves of Acokanthera oblongifolia. 14-Anhydrodigitoxigenin is a Na ⁺/K ⁺-ATPase inhibitor .

HY-B0137AS

Prilocaine-d7 hydrochloride	Isotope-Labeled Compounds Na+/K+ ATPase	Neurological Disease
Prilocaine-d₇ (hydrochloride) is deuterium labeled Prilocaine (hydrochloride). Prilocaine hydrochloride, an amino amide, is a Na, K-ATPase inhibitor. Prilocaine has neurotoxic effects .

Cat. No.	Product Name	Type

HY-D0085

DiSC3(5)

10+ Cited Publications

Fluorescent Dyes

DiSC3(5) is a fluorescent probe commonly used as a tracer dye to evaluate mitochondrial membrane potential. The excitation/emission wavelength of DiSC3(5) is up to 622/670 nm. DiSC3(5) can inhibit the respiratory system associated with mitochondrial NAD, and the IC₅₀ value is 8 μM. DiSC3(5) in the presence of Na ⁺/K ⁺-ATPase inhibitor ouabain 2 can induce membrane hyperpolarization of Ehrlich ascites tumor cells .

HY-DY1021

DiSC3(5) (solution)

Fluorescent Dyes

DiSC3 (5) (solution) is a fluorescent probe commonly used as a tracer dye to evaluate mitochondrial membrane potential. The excitation/emission wavelength of DiSC3 (5) is up to 622/670 nm. DiSC3 (5) can inhibit the respiratory system associated with mitochondrial NAD, and the IC₅₀ value is 8 μM. DiSC3 (5) in the presence of Na ⁺/K ⁺-ATPase inhibitor ouabain 2 can induce membrane hyperpolarization of Ehrlich ascites tumor cells .
Solvent and concentration: DMSO: 1 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Cat. No.	Product Name	Target	Research Area

HY-P10655

Caloxin 1C2	Proton Pump Calcium Channel	Cardiovascular Disease
Caloxin 1C2 is a specific PMCA (plasma-membrane Ca ²⁺-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The K_i values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca ²⁺ transfer. Caloxin 1C2 affects coronary contractility .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16589

Oligomycin A Maximum Cited Publications 51 Publications Verification MCH 32	Infection Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Disease Research Disease Research Fields Source Classification	ATP Synthase Fungal Antibiotic
Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial *F₀F₁-ATPase* inhibitor, with a K_i of 1 μM; Oligomycin A shows anti-fungal activity.

HY-N1724

Concanamycin A 25+ Cited Publications Antibiotic X 4357B; Folimycin; X 4357B	Infection Natural Products Microorganisms Classification of Application Fields Disease Research Fields Source Classification	Proton Pump Bacterial Antibiotic
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H ⁺-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research ^- .

HY-N0877

Bufalin 5+ Cited Publications	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	Na+/K+ ATPase
Bufalin is an active component isolated from Chan Su, acts as a potent Na ⁺/K ⁺-ATPase inhibitor, binds to the subunit α1, α2 and α3, with K_d of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-N2532

Diphyllin 3 Publications Verification	Infection Monophenols Classification of Application Fields Lignans Phenols Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Inflammation/Immunology Disease Research Fields Source Classification	VSV HIV Proton Pump Influenza Virus
Diphyllin is an orally active *V-ATPase* inhibitor (IC₅₀=17 nM) and HIV-1 inhibitor (IC₅₀=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC₅₀=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .

HY-126679

Apoptolidin	Natural Products Microorganisms Disease Research Fields Source Classification Cancer	ATP Synthase Apoptosis
Apoptolidin is a polyketide isolated from Nocardiopsis bacteria . Apoptolidin is a selective mitochondrial F₁F_O ATPase inhibitor. Apoptolidin is an apoptosis inducer and induces apoptotic cell death in cells transformed with the adenovirus type 12 oncogenes including ElA (IC₅₀=10-17 ng/ml) but not in normal cells .

HY-136933

Gitoxin	Digitalis purpurea Linn. Cardiovascular Disease Structural Classification Classification of Application Fields Scrophulariaceae Plants Disease Research Fields Steroids Source Classification	Na+/K+ ATPase
Gitoxin is a degradation metabolite of Digitoxin (HY-B1357) and a non-competitive Na ⁺/K ⁺-ATPase inhibitor, with an IC₅₀ of 1.18e-6 M against the porcine high-affinity subtype and an IC₅₀ of 2.85e-5 M against the porcine low-affinity subtype. Gitoxin regulates atrial contractility and rhythmicity. Gitoxin is applicable to research related to congestive heart failure .

HY-W754708

Ouabagenin	Microorganisms Cardiacglycosides Endogenous metabolite Steroids Source Classification	LXR Na+/K+ ATPase
Ouabagenin is a naturally occurring LXR ligand with LXR selective agonist activity. Ouabagenin acts as an EC 3.6.3.9 (Na(+)/K(+)- transport ATPase) inhibitor .

HY-125714

Isoapoptolidin	Natural Products Microorganisms Source Classification	Mitochondrial Metabolism ATP Synthase
Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (K_i>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration) .

HY-16589R

Oligomycin A (Standard) MCH 32 (Standard)	Structural Classification Microorganisms Antifungal Macrolide Antibiotics Antibiotics Disease Research Source Classification	Reference Standards ATP Synthase Fungal Antibiotic
Oligomycin A (Standard) is the analytical standard of Oligomycin A. This product is intended for research and analytical applications. Oligomycin A (MCH 32), created by Streptomyces, acts as a mitochondrial F0F1-ATPase inhibitor, with a Ki of 1 μM; Oligomycin A shows anti-fungal activity.

HY-N9456

14-Anhydrodigitoxigenin	Apocynaceae Structural Classification Acokanthera oblongifolia (Hochst.) Codd Cardiacglycosides Plants Steroids Source Classification	Na+/K+ ATPase
14-Anhydrodigitoxigenin is a cardenolides that can be isolated from the leaves of Acokanthera oblongifolia. 14-Anhydrodigitoxigenin is a Na ⁺/K ⁺-ATPase inhibitor .

HY-100801R

L-threo-3-Hydroxyaspartic acid (Standard)	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	EAAT Reference Standards
Prilocaine (hydrochloride) (Standard) is the analytical standard of Prilocaine (hydrochloride). This product is intended for research and analytical applications. Prilocaine hydrochloride, an amino amide, is a Na/K-ATPase inhibitor. Prilocaine has neurotoxic effects .

HY-N12413

Apicularen B	Natural Products Microorganisms Source Classification	Proton Pump
Apicularen B is a *V-ATPase* inhibitor and cytotoxic macrolide that can be obtained from the myxobacterium Archangium gephyra. Apicularen B can be used in the study of V-ATPase-related diseases, such as osteopetrosis .

HY-N10097

Chamigrenol	Cupressaceae Terpenoids Sesquiterpenes Plants Source Classification Thujopsis dolabrata (Thunberg ex L. f.) Sieb. et Zucc.	Na+/K+ ATPase Bacterial
Chamigrenol is a Na ⁺/K ⁺-ATPase inhibitor with an IC₅₀ value of 15.9 μg/mL. Chamigrenol shows strong inhibitory activities against Gram-positive and Gram-negative bacteria except Escherichia coli, with MIC values of 50 µg/mL .

HY-141442

Dihydronovobiocin	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial Antibiotic
Dihydronovobiocin is a bacterial inhibitor and *ATPase* inhibitor that can bind to GyrB. Dihydronovobiocin can be used to study the interaction between coumarin antibiotics (such as Novobiocin, Chlorobiocin, and Coumermycin) and DNA gyrase. Dihydronovobiocin also has the potential to study bacterial infections .

HY-136933R

Gitoxin (Standard)	Digitalis purpurea Linn. Structural Classification Scrophulariaceae Plants Steroids Source Classification	Reference Standards Na+/K+ ATPase
Gitoxin (Standard) is the analytical standard of Gitoxin. This product is intended for research and analytical applications. Gitoxin, a Na+/K+-ATPase inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably .

HY-N0877R

Bufalin (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards Na+/K+ ATPase
Bufalin (Standard) is the analytical standard of Bufalin. This product is intended for research and analytical applications. Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively . Anti-cancer activity .

HY-N13080

3-Oxo-bufalin	Microorganisms Steroids Source Classification	Others
3-Oxo-bufalin is an active compound that can be isolated from cultured toad liver tissue. 3-Oxo-bufalin can be produced through a metabolic pathway, and it is a metabolite of Bufalin (HY-N0877) catalyzed by the stereoselective 3β-dehydrogenase. Bufalin is a Na+/K+-ATPase inhibitor and has anti-tumor activity .

HY-165443

Cassaine Nervocidine	Structural Classification Erythrophleum suaveolens (Guill. et Perr.) Brenan Terpenoids Diterpenoids Plants Fabaceae Source Classification	Na+/K+ ATPase
Cassaine (Nervocidine) is a Na ⁺/K ⁺-ATPase inhibitor. Cassaine stabilizes phosphorylated intermediates, slows spontaneous dephosphorylation and blocks potassium-stimulated dephosphorylation. Cassaine exhibits non-competitive inhibition with respect to K ⁺, shows inhibition enhanced by Pi and antagonized by Na ⁺. Cassaine induces positive inotropic effects in perfused hearts with faster inotropy offset. Cassaine can be used for research on cardiac arrhythmias .

Cat. No.	Product Name	Chemical Structure

HY-B0113S

Omeprazole-d3

1 Publications Verification

Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S3

Omeprazole-13C,d3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-W008614S

Lansoprazole sulfone-d4
Lansoprazole sulfone (AG-1813)-d₄ is the deuterium labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-17507S

Pantoprazole-d6

Pantoprazole-d₆ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0137AS

Prilocaine-d7 hydrochloride
Prilocaine-d₇ (hydrochloride) is deuterium labeled Prilocaine (hydrochloride). Prilocaine hydrochloride, an amino amide, is a Na, K-ATPase inhibitor. Prilocaine has neurotoxic effects .

HY-W704786

Prilocaine Hydrochloride-d7
Prilocaine Hydrochloride-d₇ is the deuterium labeled Prilocaine hydrochloride (HY-B0137A). Prilocaine hydrochloride, an amino amide, is a Na/K-ATPase inhibitor. Prilocaine has neurotoxic effects .

HY-W008614S1

Lansoprazole sulfone-13C6
Lansoprazole sulfone (AG-1813)- ¹³C₆ is ¹³C labeled Lansoprazole sulfone (HY-W008614). Lansoprazole sulfone, Lansoprazole (HY-13662) metabolite, is a H ⁺, K ⁺-ATPase inhibitor. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .

HY-17507S1

Pantoprazole-d3

Pantoprazole-d₃ is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-W739793

Pantoprazole-d8 sodium

Pantoprazole-d₈ (BY1023-d₈) sodium is a deuterium labeled Pantoprazole (HY-17507). Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S4

Pantoprazole-d4

Pantoprazole-d₄ (BY1023-d₄) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-17507S2

Pantoprazole-d8

Pantoprazole-d₈ (BY1023-d₈) is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H ⁺/K ⁺-ATPase inhibitor with an IC₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-B0113S2

Omeprazole sulfone (methoxy-d3)

Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole sulfone. Omeprazole sulfone (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sulfone competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sulfone inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sulfone inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sulfone alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sulfone aslo has neuroprotective and antibacterial effects .

HY-B0113S5

Omeprazole-d6

Omeprazole-d₆ (H 16868-d₆) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

atpase+inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products